CTBO (Cantabio Pharmaceuticals) Total Current Liabilities: $2.22 Mil (As of Dec. 2018)


What is Cantabio Pharmaceuticals Total Current Liabilities?

Cantabio Pharmaceuticals CTBO Total Current Liabilities is $2.22 Mil as of Dec. 2018.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cantabio Pharmaceuticals's total current liabilities for the quarter that ended in Dec. 2018 was $2.22

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cantabio Pharmaceuticals Total Current Liabilities Related Terms

Cantabio Pharmaceuticals Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Total Current Liabilities Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Total Current Liabilities
Get a 7-Day Free Trial 0.01 0.22 0.42 0.89 1.98

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 1.98 2.49 2.44 2.22

Cantabio Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cantabio Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Mar. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.778+1.205
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.98

Cantabio Pharmaceuticals's Total Current Liabilities for the quarter that ended in Dec. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.806+1.409
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $2.22 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Total Current Liabilities of $2.22 Mil as of Dec. 2018. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Total Current Liabilities too high?
Cantabio Pharmaceuticals' current Total Current Liabilities is $2.22 Mil.
How does Cantabio Pharmaceuticals' Total Current Liabilities compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Total Current Liabilities of $2.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Total Current Liabilities is $2.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Total Current Liabilities of $2.22 Mil. The current Total Current Liabilities is $2.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Total Current Liabilities is $2.22 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.